Incoherent field sonodynamic therapy for treating cancer
Ultrasound transducer element arrays using acoustic ensonification drive patterns via a patient interface for sonosensitizer activation in sonodynamic therapy. Incoherent acoustic field generation varying phase, frequencies, and/or amplitude via controlled delivery of low intensity planar acoustic waves. Method includes generating a first and a second signal to generate respective acoustic ensonification drive patterns with phase, frequency, and amplitude and generating at least one relative phase, frequency or amplitude difference to generate a third incoherent acoustic ensonification pattern to activate a sonosensitizer. Calibration and complementary therapy procedures to improve cell susceptibility of cells to sonodynamic therapy are disclosed.
1. An ultrasound transducer system that generates an incoherent acoustic pressure field for activating a sonosensitizer in conjunction with providing sonodynamic therapy, the ultrasound transducer system comprising:
an ultrasound transducer array comprising a plurality of ultrasonic piezoelectric transducer elements,
wherein the plurality of ultrasonic piezoelectric transducer elements is configured to generate the incoherent acoustic pressure field via an aperture sized and configured with an energy profile to saturate a treatment volume to ensure treatment of a targeted lesion of cancer cells and extraneous cancer cells located within a tissue of a patient by activating the sonosensitizer located within the tissue of the patient,
wherein the ultrasound transducer array comprises an array dimension,
wherein each of the ultrasonic piezoelectric transducer elements in the plurality of ultrasonic piezoelectric transducer elements comprises a dimension in a range of 0.5 mm to 20 mm,
wherein the aperture comprises an aperture size,
wherein the targeted lesion of cancer cells comprises a lesion size,
wherein the aperture size is selected to be larger than the lesion size, such that an aspect ratio of the aperture size to the lesion size enables initiation of the incoherent acoustic pressure field to treat the targeted lesion of cancer cells and the extraneous cancer cells in the tissue,
wherein the plurality of ultrasonic piezoelectric transducer elements is driven by a signal to generate the incoherent acoustic pressure field, wherein the signal comprises one or more of the group consisting of:
a modulated phase across the plurality of ultrasonic piezoelectric transducer elements,
a modulated frequency across the plurality of ultrasonic piezoelectric transducer elements, and
a modulated amplitude across the plurality of ultrasonic piezoelectric transducer elements;
wherein each ultrasonic piezoelectric transducer element in the plurality of ultrasonic piezoelectric transducer elements comprises an emitting surface configured to emit planar acoustic waves or defocused acoustic waves,
wherein the signal is configured to minimize a spatial variation of an acoustic wave intensity to activate the sonosensitizer at the targeted lesion of cancer cells with the planar acoustic waves or the defocused acoustic waves, and
wherein the signal is configured with a duty cycle to drive each ultrasonic piezoelectric transducer element in the plurality of ultrasonic piezoelectric transducer elements to generate (i) a high temporal peak acoustic intensity sufficient to activate the sonosensitizer at the targeted lesion of cancer cells with the planar acoustic waves or the defocused acoustic waves and (ii) a low temporal average acoustic intensity to preserve tissue.
2. The ultrasound transducer system of claim 1 , wherein the signal comprises the modulated phase across the plurality of ultrasonic piezoelectric transducer elements, and wherein the modulated phase comprises a randomized phase difference.
3. The ultrasound transducer system of claim 1 , wherein the plurality of ultrasonic piezoelectric transducer elements comprises over 128 ultrasonic piezoelectric transducer elements.
4. The ultrasound transducer system of claim 1 , further comprising a cooling system configured to remove excess heat from the patient, wherein the cooling system comprises a flexible cavity configured for circulation of a cooling fluid.
5. The ultrasound transducer system of claim 1 , wherein the energy profile is driven at ultrasonic frequencies in a range of 20 kHz to 2 MHz.
6. The ultrasound transducer system of claim 1 , wherein the sonosensitizer is selected from the group consisting of: aminolevulinic acid (ALA), hematoporphyrin, Rose Bengal, curcumin, titanium nanoparticles, and chlorine e6.
7. The ultrasound transducer system of claim 1 , wherein the ultrasound transducer system is configured for treating cancerous tissue in a brain, lung, breast, liver, stomach, prostate, vagina, testes, pancreas, or intestines.
8. The ultrasound transducer system of claim 1 , wherein the plurality of ultrasonic piezoelectric transducer elements are disposed on a patient interface configured to couple to a head of the patient.
9. The ultrasound transducer system of claim 1 , wherein the plurality of ultrasonic piezoelectric transducer elements are disposed on a helmet configured to couple to a head of the patient.
10. The ultrasound transducer system of claim 1 , wherein the plurality of ultrasonic piezoelectric transducer elements comprises between 128 to 1024 ultrasonic piezoelectric transducer elements.
11. An ultrasound transducer system that generates an incoherent acoustic pressure field for activating a sonosensitizer in conjunction with providing sonodynamic therapy, the ultrasound transducer system comprising:
an ultrasound transducer array comprising a plurality of ultrasonic piezoelectric transducer elements,
wherein the plurality of ultrasonic piezoelectric transducer elements is configured to generate the incoherent acoustic pressure field via an aperture sized and configured with an energy profile to saturate a large treatment volume to ensure treatment of a targeted lesion of cancer cells and extraneous cancer cells located within a tissue of a patient by activating the sonosensitizer located within the tissue of the patient,
wherein each ultrasonic piezoelectric transducer element in the plurality of ultrasonic piezoelectric transducer elements comprises an emitting surface configured to emit planar acoustic waves or defocused acoustic waves,
wherein each of the ultrasonic piezoelectric transducer elements in the plurality of ultrasonic piezoelectric transducer elements comprises a dimension,
wherein the aperture comprises an aperture size,
wherein the targeted lesion of cancer cells comprises a lesion size,
wherein the aperture size is selected to be larger than the lesion size, such that an aspect ratio of the aperture size to the lesion size enables initiation of the incoherent acoustic pressure field to treat the targeted lesion of cancer cells and the extraneous cancer cells in the tissue,
wherein the plurality of ultrasonic piezoelectric transducer elements is driven by a signal to generate the incoherent acoustic pressure field, wherein the signal comprises a modulated phase across the plurality of ultrasonic piezoelectric transducer elements,
wherein the signal is configured to minimize a spatial variation of an acoustic wave intensity to activate the sonosensitizer at the targeted lesion of cancer cells with the planar acoustic waves or the defocused acoustic waves,
wherein the signal is configured with a duty cycle to drive each ultrasonic piezoelectric transducer element in the plurality of ultrasonic piezoelectric transducer elements to generate (i) a high temporal peak acoustic intensity sufficient to activate the sonosensitizer at the targeted lesion of cancer cells with the planar acoustic waves or the defocused acoustic waves and (ii) a low temporal average acoustic intensity to preserve tissue.
12. The ultrasound transducer system of claim 11 , wherein the plurality of ultrasonic piezoelectric transducer elements are arranged in a hemispherical arrangement.
13. The ultrasound transducer system of claim 11 , further comprising a therapy selected from radiation, chemotherapy, immunotherapy, radiotherapy, and hyperthermia.
14. The ultrasound transducer system of claim 11 , wherein the plurality of ultrasonic piezoelectric transducer elements is acoustically coupled to the patient via a fluid filled cavity.
15. The ultrasound transducer system of claim 11 , wherein the ultrasound transducer system is configured for treating cancerous tissue in a brain, lung, breast, liver, stomach, prostate, vagina, testes, pancreas, or intestines.
16. The ultrasound transducer system of claim 11 , wherein the sonosensitizer is selected from the group consisting of: aminolevulinic acid (ALA), hematoporphyrin, Rose Bengal, curcumin, titanium nanoparticles, and chlorine e6.
17. The ultrasound transducer system of claim 11 , wherein the plurality of ultrasonic piezoelectric transducer elements comprises between 128 to 1024 ultrasonic piezoelectric transducer elements.
18. The ultrasound transducer system of claim 11 , wherein the modulated phase comprises a randomized phase difference.
19. The ultrasound transducer system of claim 11 , further comprising a cooling system configured to remove excess heat from the patient, wherein the cooling system comprises a flexible cavity configured for circulation of a cooling fluid.
20. The ultrasound transducer system of claim 11 , wherein the energy profile is driven at ultrasonic frequencies in a range of 20 kHz to 12 MHz.